Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pbc.30961 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing Effects of Olaparib by Alpha- and Beta-Emitting Radionuclides, X-Rays, and Ultraviolet A Light in Combination with Ortho-IodoHoechst in a Prostate Cancer Cell Model.
Pharmaceuticals (Basel)
October 2024
Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, D-01307 Dresden, Germany.
New therapeutic strategies for metastatic castration-resistant prostate cancer (mCRPC) have been developed in the past to achieve the best response rates. Most recently, the use of combination therapies has been explored to optimize patient outcomes. Poly(ADP-ribose) polymerase inhibitors (PARPi) may help to treat mCRPC more effectively.
View Article and Find Full Text PDF[Ac]Ac-PSMA for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
Eur J Clin Invest
November 2024
Nuclear Medicine, Gruppo Ospedaliero Moncucco, Clinica Moncucco, Lugano, Switzerland.
Background: Approximately 10%-20% of prostate cancers progress to metastatic and castration-resistant forms (mCRPC). Radioligand (RLT) therapy with [Lu]Lu-prostate-specific membrane antigen (PSMA) is an approved treatment for metastasized mCRPC. Moreover, Actinium-225 (Ac), an alpha-emitter isotope, has also been used to label PSMA and, recently, to treat mCRPC patients with encouraging results.
View Article and Find Full Text PDFBone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies.
Diagnostics (Basel)
October 2024
Department of Radiological Sciences, Faculty of Applied Medical Sciences, Najran University, Najran 61441, Saudi Arabia.
Recent advances have broadened the range of therapeutic options for mCRPC, with several new treatments, including novel hormonal therapies (enzalutamide, abiraterone), chemotherapeutic agents (docetaxel, cabazitaxel), immunotherapies (sipuleucel-T), and bone targeting radiopharmaceuticals (radium-223) showing improved clinical outcomes and receiving U.S. Food and Drug Administration approval.
View Article and Find Full Text PDFFeasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors.
J Nucl Med
December 2024
Department of Nuclear Medicine, University Medical Center, Mainz, Germany;
Radiopharmaceutical therapies (RPTs) based on fibroblast activation protein (FAP) and FAP inhibitors (FAPIs) are a new option for progressive metastatic cancer in patients pretreated multiple times. To date, published in-human data refer to initial experiences with β-emitting Y- and Lu-based RPT. However, the short tumor retention time of FAPI ligands is considered a major limitation of FAPI RPT.
View Article and Find Full Text PDFFeasibility and safety of endoscopic ultrasound-guided diffusing alpha emitter radiation therapy for advanced pancreatic cancer: Preliminary data.
Endosc Int Open
October 2024
Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, Canada.
Article Synopsis
- Pancreatic cancer has limited treatment options, and a new method called Alpha DaRT, using alpha-particle radiation therapy, is being tested to improve outcomes.
- A study evaluated the safety and feasibility of using EUS-guided Alpha DaRT to treat patients with advanced, inoperable pancreatic cancer, with procedures conducted successfully between March and September 2023.
- Results showed that while some adverse events occurred, most were related to disease progression rather than the treatment, and preliminary findings indicate that this approach is both feasible and safe, warranting further investigation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!